PLoS ONE (Jan 2014)

BCR-ABL promotes PTEN downregulation in chronic myeloid leukemia.

  • Cristina Panuzzo,
  • Sabrina Crivellaro,
  • Giovanna Carrà,
  • Angelo Guerrasio,
  • Giuseppe Saglio,
  • Alessandro Morotti

DOI
https://doi.org/10.1371/journal.pone.0110682
Journal volume & issue
Vol. 9, no. 10
p. e110682

Abstract

Read online

Chronic myeloid leukemia (CML) is a myeloproliferative disorder characterized by the t(9;22) translocation coding for the chimeric protein p210 BCR-ABL. The tumor suppressor PTEN plays a critical role in the pathogenesis of CML chronic phase, through non genomic loss of function mechanisms, such as protein down-regulation and impaired nuclear/cytoplasmic shuttling. Here we demonstrate that BCR-ABL promotes PTEN downregulation through a MEK dependent pathway. Furthermore, we describe a novel not recurrent N212D-PTEN point mutation found in the EM2 blast crisis cell line.